The Link Between Coffee, Caffeine, and Gout Flare-Ups

by Sanjay | Mar 31, 2025 | Gout, Safe Foods

Introduction

Gout is a type of inflammatory arthritis caused by the buildup of uric acid crystals in the joints. It can lead to painful flare-ups, swelling, and stiffness. Many gout patients wonder how their caffeine intake, particularly from coffee, might impact their condition.

The research on the relationship between caffeine, coffee, and gout is mixed, with some studies suggesting caffeine may help, while others indicate it could potentially worsen symptoms. Let’s take a closer look at the evidence.

The Potential Benefits of Caffeine for Gout

Several studies have found that increased coffee consumption is associated with lower uric acid levels and a reduced risk of developing gout (Choi & Curhan, 2007, pp. 816–821), (Kiyohara et al., 1999, pp. 125–130). The proposed mechanisms include:

Diuretic Effect: Caffeine has a mild diuretic effect, which can increase uric acid excretion through the kidneys (Bhaktha et al., 2016, pp. 393–395), (Choi & Curhan, 2007, pp. 816–821).
Antioxidant Properties: Coffee contains antioxidants that may help reduce inflammation associated with gout flare-ups (Cutler et al., 2015, pp. 2233–2238).
Metabolic Changes: Caffeine may influence purine metabolism and lower uric acid production in the body (Wen et al., 2024), (Matsumura et al., 2019).

A 2007 study followed over 45,000 men for 12 years and found that increasing coffee intake was associated with a decreased risk of developing gout. Men who drank 6 or more cups of coffee per day had a 59% lower risk of gout compared to non-coffee drinkers (Choi & Curhan, 2007, pp. 816–821).

The Potential Drawbacks of Caffeine for Gout

However, not all research supports the idea that caffeine is beneficial for gout. Some studies have found that high doses of caffeine may actually increase uric acid levels and the risk of gout flare-ups (Liu et al., 2022, pp. 391–399), (Kamely et al., 2016, pp. 2673–2678). The proposed mechanisms include:

Dehydration: Caffeine can have a diuretic effect, leading to dehydration, which may increase uric acid concentrations in the body (Zavvos et al., 2020, pp. 288–293).
Metabolic Changes: In some individuals, caffeine may alter purine metabolism in a way that increases uric acid production (Balasubramanian, 2003, pp. 930–936), (Kamely et al., 2016, pp. 2673–2678).

A 2022 study found an inverted U-shaped relationship between caffeine intake and serum uric acid levels, meaning moderate caffeine intake was associated with lower uric acid, but very high or very low intake was linked to higher uric acid (Liu et al., 2022, pp. 391–399).

Balancing Caffeine Intake for Gout Management

The research suggests that moderate coffee or caffeine consumption (around 1-3 cups per day) may be beneficial for gout, while excessive intake could potentially worsen symptoms. However, individual responses can vary.

It’s important for gout patients to pay attention to how their body reacts to caffeine and adjust their intake accordingly. Staying hydrated, maintaining a healthy diet, and working closely with a healthcare provider are also crucial for managing gout effectively.

Conclusion

The relationship between caffeine, coffee, and gout is complex. While some studies suggest moderate caffeine intake may help lower uric acid and reduce gout risk, others indicate high doses could potentially exacerbate symptoms. Gout patients should experiment with their caffeine intake and monitor how it affects their condition. Maintaining overall healthy lifestyle habits is key for managing gout successfully.

Bibliography:

Abulfadle, K., Bakhaat, G., Rahiman, S., & Tantry, B. (2015). Effect of Excessive Green Tea Versus Fluoride and Caffeine on Body Weight and Serum Thyroid Hormones in Male Mice. Journal of Physiology and Pharmacology Advances, 5, 565–573.

Agrawal, M., Niroula, A., Cunin, P., McConkey, M., Kovalcik, V., Kim, P. G., Wong, W., Weeks, L., Lin, A. E., Miller, P., Gibson, C., Sekar, A., Schaefer, I., Neuberg, D., Stone, R., Bick, A., Uddin, M., Griffin, G., Jaiswal, S., … Ebert, B. (2022). TET2-mutant clonal hematopoiesis and risk of gout. Blood, 140, 1094–1103.

Aydın, Ü. F., Kozanoğlu, E., & Tuli, A. (2024). High Fructose Consumption and Metabolic Syndrome from Gout Perspective. Cerrahpasa Medical Journal.

Bae, J., Park, P., Chun, B., Choi, B., Kim, M. K., Shin, M., Lee, Y.-H., Shin, D., & Kim, S.-K. (2014). The effect of coffee, tea, and caffeine consumption on serum uric acid and the risk of hyperuricemia in Korean Multi-Rural Communities Cohort. Rheumatology International, 35, 327–336.

Balasubramanian, T. (2003). Uric Acid or 1-Methyl Uric Acid in the Urinary Bladder Increases Serum Glucose, Insulin, True Triglyceride, and Total Cholesterol Levels in Wistar Rats. TheScientificWorldJournal, 3, 930–936.

Bhaktha, G., Shantaram, M., & Nayak, S. (2016). BENEFICIAL EFFECTS OF COFFEE AND MAINTENANCE OF URIC ACID LEVELS. International Journal of Pharmacy and Pharmaceutical Sciences, 8, 393–395.

Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J., Lurbe, E., Mancia, G., Redón, J., Stack, A., & Tsioufis, K. (2020). Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine.

Burhan, A., Usmar, U., Zulham, Z., & Andarwiyati, A. (2018). The effect of kersen’s skin infusion (Muntingia calabura L.) on blood uric acid levels of the rats (Rattus novergicus). Jurnal Kedokteran Dan Kesehatan Indonesia.

Carvalho, A., Marticorena, F., Grecco, B., Barreto, G., & Saunders, B. (2022). Can I Have My Coffee and Drink It? A Systematic Review and Meta-analysis to Determine Whether Habitual Caffeine Consumption Affects the Ergogenic Effect of Caffeine. Sports Medicine, 52, 2209–2220.

Chen, C. K., & Rosli, M. A. M. (2018). Effect of caffeine consumption prior to walking exercise on body composition in overweight individuals. 13.

Chen, P.-E., Liu, C.-Y., Chien, W.-H., Chien, C.-W., & Tung, T. (2019). Effectiveness of Cherries in Reducing Uric Acid and Gout: A Systematic Review. Evidence-Based Complementary and Alternative Medicine, 2019.

Chen-Xu, M., Yokose, C., Rai, S., Pillinger, M., & Choi, H. K. (2019). Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis & Rheumatology, 71.

Choi, H. K., & Curhan, G. (2007). Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis & Rheumatism, 57 5, 816–821.

Cipolletta, E., Tata, L., Nakafero, G., Avery, A., Mamas, M., & Abhishek, A. (2022). Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. Journal of the American Medical Association (JAMA), 328 5, 440–450.

Cutler, R., Camandola, S., Malott, K. F., Edelhauser, M. A., & Mattson, M. (2015). The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders. Current Topics in Medicinal Chemistry, 15 21, 2233–2238.

Dehlin, M., Jacobsson, L., & Roddy, E. (2020). Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology, 16, 380–390.

Duncan, M., Dobell, A., Caygill, C. L., Eyre, E. L. J., & Tallis, J. (2018). The effect of acute caffeine ingestion on upper body anaerobic exercise and cognitive performance. European Journal of Sport Science, 19, 103–111.

Duncan, M., Dobell, A., Caygill, C. L., Eyre, E. L. J., & Tallis, J. (2019). The effect of acute caffeine ingestion on repeated upper body anaerobic exercise and cognitive performance.

Duncan, M., Eyre, E., Grgic, J., & Tallis, J. (2019). The effect of acute caffeine ingestion on upper and lower body anaerobic exercise performance. European Journal of Sport Science, 19, 1359–1366.

Elbendary, E. Y., Mahmoud, M., Salem, S. F., & Farah, A. (2023). The Effects of Energy Drink Consumption on Kidney and Liver Function: A Comparative Study. The Journal of Bioscience and Medicine.

Ferragut, C., Gonzalo-Encabo, P., López-Samanés, Á., Valadés, D., & Pérez‐López, A. (2024). Effect of Acute Sodium Bicarbonate and Caffeine Coingestion on Repeated-Sprint Performance in Recreationally Trained Individuals: A Randomized Controlled Trial. International Journal of Sports Physiology and Performance, 1–8.

Filip-Stachnik, A., Krzysztofik, M., Coso, J. D., Pałka, T., & Sadowska-Krępa, E. (2023). The Effect of Acute Caffeine Intake on Resistance Training Volume, Prooxidant-Antioxidant Balance and Muscle Damage Markers Following a Session of Full-Body Resistance Exercise in Resistance-Trained Men Habituated to Caffeine. Journal of Sports Science and Medicine, 22 3, 436–446.

Filip-Stachnik, A., Spieszny, M., Stanisz, L., & Krzysztofik, M. (2022). Does caffeine ingestion affect the lower-body post-activation performance enhancement in female volleyball players? BMC Sports Science, Medicine and Rehabilitation, 14.

Fitzgerald, J., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A., Gelber, A., Harrold, L., Khanna, D., King, C., Levy, Gerald. D., Libbey, C., Mount, D., Pillinger, M., Rosenthal, A., Singh, J., Sims, J. E., Smith, B. J., Wenger, N., … Neogi, T. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology, 72.

Giráldez-Costas, V., Coso, J. D., Mañas, A., & Salinero, J. (2023). The Long Way to Establish the Ergogenic Effect of Caffeine on Strength Performance: An Overview Review. Nutrients, 15.

Główka, N., Malik, J., Podgórski, T., Stemplewski, R., Maciaszek, J., Ciążyńska, J., Zawieja, E. E., Chmurzyńska, A., Nowaczyk, P., & Durkalec-Michalski, K. (2024). The dose-dependent effect of caffeine supplementation on performance, reaction time and postural stability in CrossFit – a randomized placebo-controlled crossover trial. Journal of the International Society of Sports Nutrition, 21.

Hasibuan, S. B. (2018). CORRELATION BETWEEN THE CONSUMPTION OF TEA DRINK WITH URIC ACID LEVEL OF THE STUDENTS AT SETIA BUDI UNIVERSITY SURAKARTA) Sartika.

He, Q., Mok, T., Sin, T.-H., Yin, J., Li, S., Yin, Y., Ming, W., & Feng, B. (2023). Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction. JMIR Public Health and Surveillance, 9.

Hursel, R., & Westerterp-Plantenga, M. (2009). Green tea catechin plus caffeine supplementation to a high protein diet has no additional effect on body weight maintenance after weight loss. Appetite, 52.

Jiang, J., Zhang, T., Liu, Y., Chang, Q., Zhao, Y., Guo, C., & Xia, Y. (2023). Prevalence of Diabetes in Patients with Hyperuricemia and Gout: A Systematic Review and Meta-analysis. Current Diabetes Reports, 23, 103–117.

Kamely, M., Torshizi, M. A. K., & Rahimi, S. (2016). Blood biochemistry, thyroid hormones, and performance in broilers with ascites caused by caffeine. Poultry Science, 95 11, 2673–2678.

Kiyohara, C., Kono, S., Honjo, S., Todoroki, I., Sakurai, Y., Nishiwaki, M., Hamada, H., Nishikawa, H., Koga, H., Ogawa, S., & Nakagawa, K. (1999). Inverse association between coffee drinking and serum uric acid concentrations in middle-aged Japanese males. British Journal of Nutrition, 82, 125–130.

Kolber, M., & Ton, J. (2020). Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al. Arthritis & Rheumatology, 73.

Kowalczyk, N. S., Prochaska, M., & Worcester, E. (2023). Metabolomic profiles and pathogenesis of nephrolithiasis. Current Opinion in Nephrology and Hypertension, 32, 490–495.

Kuo, C., Grainge, M., Zhang, W., & Doherty, M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews Rheumatology, 11, 649–662.

Larsson, S., Woolf, B., & Gill, D. (2023). Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease: two sample mendelian randomisation study. BMJ Medicine, 2, 1–8.

Lenasi, H., Rihar, E., Filipič, J., Klemenc, M., & Fister, P. (2023). The Effect of Caffeine on Heart Rate Variability in Newborns: A Pilot Study. Life, 13.

Lima-Silva, A., Cristina-Souza, G., Silva-Cavalcante, M., Bertuzzi, R., & Bishop, D. (2021). Caffeine during High-Intensity Whole-Body Exercise: An Integrative Approach beyond the Central Nervous System. Nutrients, 13.

Limirio, L. S., Santos, H. O., Reis, A. S., & Oliveira, E. P. (2021). Association Between Dietary Intake and Serum Uric Acid Levels in Kidney Transplant Patients. Journal of Renal Nutrition.

Liu, A. G., Arceneaux, K. P., Chu, J., Jacob, G., Schreiber, A. L., Tipton, R., Yu, Y., Johnson, W., Greenway, F., & Primeaux, S. (2015). The effect of caffeine and albuterol on body composition and metabolic rate. Obesity, 23.

Liu, A., Jiang, C., Liu, Q., Yin, H., Zhou, H., Ma, H., & Geng, Q. (2022). The Inverted U-Shaped Association of Caffeine Intake with Serum Uric Acid in U.S. Adults. The Journal of Nutrition, Health & Aging, 26, 391–399.

Marinho, A., Cristina-Souza, G., Santos, P. S., Santos-Mariano, A. C., Rodacki, A., De-Oliveira, F., Bertuzzi, R., & Lima-Silva, A. (2022). Caffeine alters the breathing pattern during high-intensity whole-body exercise in healthy men. European Journal of Applied Physiology, 122, 1497–1507.

Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440, 237–241.

Matsumura, N., & Aoyama, K. (2023). Glutathione-Mediated Neuroprotective Effect of Purine Derivatives. International Journal of Molecular Sciences, 24.

Matsumura, N., Kinoshita, C., Kikuchi-Utsumi, K., Nakaki, T., & Aoyama, K. (2019). A possible mechanism of caffeine metabolites on cysteine uptake in hippocampal neurons. Proceedings for Annual Meeting of The Japanese Pharmacological Society.

Megawati, M., & Nur, F. (2021). The Effect of Sidaguri Leaf Infusa (Sida rhombifolia L) On Uric acid levels in mice Male (Mus musculus). Jurnal Farmasi Sandi Karsa.

Merino-Fernández, M., Giráldez-Costas, V., González-García, J., Gutiérrez-Hellín, J., González-Millán, C., Matos-Duarte, M., & Ruíz-Moreno, C. (2022). Effects of 3 mg/kg Body Mass of Caffeine on the Performance of Jiu-Jitsu Elite Athletes. Nutrients, 14.

Musdja, M. Y., Azter, A. A., & Musir, A. (2019). The Effect of Ethanol Extract of Elephantopus scaber Linn in Decreasing Blood Uric Acid Levels of Hyperuricemic Male Rats. European Journal of Medicinal Plants.

Neogi, T., Jansen, T., Dalbeth, N., Fransen, J., Schumacher, H., Berendsen, D., Brown, M., Choi, H. K., Edwards, N., Janssens, H., Lioté, F., Naden, R., Nuki, G., Ogdie, A., Pérez-Ruiz, F., Saag, K., Singh, J. A., Sundy, J., Tausche, A., … Taylor, W. (2015). 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 74, 1789–1798.

Onder, M. E., & Zengin, O. (2021). YouTube as a source of information on gout: a quality analysis. Rheumatology International, 41, 1321–1328.

Pratama, F. A., Aisyafalah, S., & Kurnijasanti, R. (2024). Effectiveness of Bay Leaf Extract (Syzygium polyanthum) on Uric Acid and Cholesterol Levels in Caffeine-Induced Male Mice (Mus musculus). Journal of Basic Medical Veterinary.

Radenkovic, S., Stojanovic, D., Milojkovic, B., & Radović, J. (2015). 9A.02 SODIUM SENSITIVE HYPERTENSION: CAN IT BE ASSESSED BY MEASURING URIC ACID LEVELS?

Rahimi, M., Semenova, E., John, G., Fallah, F., Larin, A., Generozov, E., & Ahmetov, I. (2024). Effect of ADORA2A Gene Polymorphism and Acute Caffeine Supplementation on Hormonal Response to Resistance Exercise: A Double-Blind, Crossover, Placebo-Controlled Study. Nutrients, 16.

Reddy, R. (2021). Monoarticular Crystal Arthropathy of the Knee: Tophaceous Gout. Dubai Medical Journal, 5, 41–45.

Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castaneda, J. F., Coyfish, M., Guillo, S., Jansen, T., Janssens, H., Lioté, F., Mallen, C., Nuki, G., Pérez-Ruiz, F., Pimentão, J., Punzi, L., Pywell, A., So, A., Tausche, A., … Bardin, T. (2019). 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases, 79, 31–38.

Robles-González, L., Maldonado, M. R., Alcalá-Escamilla, J. C., Jurado-Fasoli, L., Miras-Moreno, S., Soriano, M., García‐Ramos, A., Ruiz, J. R., & Amaro-Gahete, F. (2022). Caffeine ingestion attenuates diurnal variation of lower-body ballistic performance in resistance-trained women. European Journal of Sport Science, 23, 381–392.

Rodriguez, C., & Bhattacharyya, A. (2016). Are dietary modifications effective for preventing gout attacks.

Rozza, F., Trimarco, V., Izzo, R., Grassi, D., & Ferri, C. (2016). Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients. High Blood Pressure & Cardiovascular Prevention, 23, 381–386.

Ruiz-Fernández, I., Valadés, D., Domínguez, R., Ferragut, C., & Pérez‐López, A. (2023). Load and muscle group size influence the ergogenic effect of acute caffeine intake in muscular strength, power and endurance. European Journal of Nutrition, 62, 1783–1794.

Singh, J., & Gaffo, A. (2020). Gout epidemiology and comorbidities. Seminars in Arthritis & Rheumatism, 50 3S, S11–S16.

Siquier-Coll, J., Delgado-García, G., Soto-Méndez, F., Liñán-González, A., García, R., & González-Férnandez, F. (2023). The Effect of Caffeine Supplementation on Female Volleyball Players’ Performance and Wellness during a Regular Training Week. Nutrients, 16.

Song, J., Jin, C., Shan, Z., Teng, W., & Li, J. (2022). Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China. Journal of Translational Internal Medicine, 10, 134–145.

Strachecka, A., Krauze, M., Olszewski, K., Borsuk, G., Paleolog, J., Merska, M., Chobotow, J., Bajda, M., & Grzywnowicz, K. (2014). Unexpectedly strong effect of caffeine on the vitality of western honeybees (Apis mellifera). Biochemistry (Moscow), 79, 1192–1201.

Tumas, V., Aureliano, M. J., Mello Rieder, C. R., Schuh, A. F. S., Ferraz, H. B., Borges, V., Soares, M. C., Boone, D. L., Silva, C., Costa, M. C., Silva, D. J., Carmo, A. V., Rezende Mikael, L., Santos-Lobato, B. L., Rosso, A. L., Vilaça, C., Braga-Neto, P., Gomes, A. B. F., Carvalho, C. G. M., … Mata, I. (2025). Modifiable risk factors associated with the risk of developing Parkinson’s disease: a critical review. Arquivos de Neuro-Psiquiatria, 83 3, 1–10.

Venkatachalam, C., & Sengottian, M. (2016). Study on Roasted Date Seed Non Caffeinated Coffee Powder as a Promising Alternative. Asian Journal of Research in Social Sciences and Humanities, 6, 1387–1394.

Wang, Z., Li, Y., Liao, W., Huang, J., Liu, Y., Li, Z., & Tang, J. (2022). Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. Frontiers in Cellular and Infection Microbiology, 12.

Wargniez, W., Connétable, S., Bourokba, N., Dufour, O., Nouveau, S., & Grégoire, S. (2022). In-Vivo Tape Stripping Study with Caffeine for Comparisons on Body Sites, Age and Washing. Pharmaceutical Research, 39, 1935–1944.

Wen, S., Arakawa, H., Yokoyama, S., Shirasaka, Y., Higashida, H., & Tamai, I. (2024). Functional identification of soluble uric acid as an endogenous inhibitor of CD38. bioRxiv, 13.

White, W., Saag, K., Becker, M., Borer, J., Gorelick, P., Whelton, A., Hunt, B., Castillo, M., & Gunawardhana, L. (2018). Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 378, 1200–1210.

Yildirim, U. C., Akçay, N., Alexe, D., Esen, O., Gulu, M., Cîrtiţă-Buzoianu, C., Cinarli, F. S., Cojocaru, M., Sari, C., Alexe, C. I., & Karayiğit, R. (2023). Acute effect of different doses of caffeinated chewing gum on exercise performance in caffeine-habituated male soccer players. Frontiers in Nutrition, 10.

Yokose, C., McCormick, N., Lu, N., Tanikella, S., Lin, K., Joshi, A., Raffield, L., Warner, E. T., Merriman, T., Hsu, J., Saag, K., Zhang, Y., & Choi, H. K. (2023). Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. JAMA Network Open, 6.

Yong-Chu, Sun, S., Huang, Y., Gao, Q., Xie, X., Wang, P., Li, J., Liang, L., He, X., Jiang, Y., Wang, M., Yang, J., Chen, X., Zhou, C., Zhao, Y., Ding, F., Zhang, Y., Wu, X., Xue-Bai, … Huang, R. (2021). Metagenomic analysis revealed the potential role of gut microbiome in gout. Npj Biofilms and Microbiomes, 7.

Zavvos, A., Miliotis, P. G., Stergiopoulos, D. C., Koskolou, M., & Geladas, N. (2020). The Effect of Caffeine Intake on Body Fluids Replacement After Exercise-Induced Dehydration. Nutrition Today, 55, 288–293.

Zhang, Y., Chen, S., Yuan, M., Xu, Y., & Xu, H. (2022). Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients, 14.

Zhao, J., Wei, K.-S., Jiang, P., Chang, C., Xu, L., Xu, L., Shi, Y., Guo, S., Xue, Y., & He, D. (2022). Inflammatory Response to Regulated Cell Death in Gout and Its Functional Implications. Frontiers in Immunology, 13.

Zhu, B., Yi-Wang, Zhou, W., Jin, S., Shen, Z., Zhang, H., Zhang, X., Ding, X., & Li, Y. (2022). Trend dynamics of gout prevalence among the Chinese population, 1990-2019: A joinpoint and age-period-cohort analysis. Frontiers in Public Health, 10.

Zhu, Y., Pandya, B. J., & Choi, H. K. (2011). Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis & Rheumatism, 63 10, 3136–3141.

Soothe the Pain: How Gout Massage Can Help Alleviate Symptoms

by Sanjay | Jan 30, 2025 | Gout

Gout is a form of inflammatory arthritis characterized by sudden and severe pain, redness, and swelling in the joints, most commonly affecting the big toe. This condition arises from an excess of uric acid in the bloodstream, which can crystallize and deposit in the joints, leading to intense discomfort. Factors contributing to elevated uric acid levels include dietary choices, obesity, certain medications, and genetic predisposition.

Foods rich in purines, such as red meat, shellfish, and sugary beverages, can exacerbate the condition by increasing uric acid production. The symptoms of gout typically manifest in acute episodes known as gout attacks. These attacks can occur suddenly, often at night, and may last for several days to weeks if untreated.

During an attack, the affected joint becomes extremely tender, making even the lightest touch unbearable. Other symptoms may include fever, chills, and a general feeling of malaise. Understanding these symptoms is crucial for early intervention and management of gout, as timely treatment can help prevent further complications and chronic joint damage.

Key Takeaways

Gout is a form of arthritis caused by a buildup of uric acid in the body, leading to painful joint inflammation.
Massage therapy can help alleviate gout symptoms by reducing inflammation, improving circulation, and promoting relaxation.
Techniques for gout massage include gentle pressure, stretching, and joint mobilization to relieve pain and improve mobility.
Self-massage at home can be effective for managing gout symptoms, using techniques such as gentle rubbing and applying pressure to affected joints.
Incorporating gout massage into a holistic treatment plan, along with medication, diet, and lifestyle changes, can help manage symptoms and improve overall well-being.

The Benefits of Massage Therapy for Gout

Massage therapy can serve as a complementary approach to managing gout symptoms. One of the primary benefits of massage is its ability to promote relaxation and reduce stress, which can be particularly beneficial for individuals experiencing the pain and discomfort associated with gout attacks. Stress can exacerbate inflammation in the body, so finding ways to alleviate it can contribute to overall symptom relief.

Additionally, massage can improve circulation in the affected areas, potentially aiding in the removal of uric acid crystals and reducing swelling. Furthermore, massage therapy can help alleviate muscle tension that may develop around inflamed joints. When a gout attack occurs, individuals often adopt protective postures to avoid pain, leading to stiffness and discomfort in surrounding muscles.

By addressing these muscle tensions through targeted massage techniques, individuals may experience improved mobility and a reduction in pain levels. Overall, incorporating massage therapy into a gout management plan can enhance physical comfort and emotional well-being.

Techniques for Gout Massage

When considering massage techniques for gout relief, it is essential to approach the affected area with care and gentleness. One effective technique is effleurage, which involves long, sweeping strokes that promote relaxation and increase blood flow without applying excessive pressure. This technique can be particularly soothing during a gout attack when the joint is sensitive to touch.

Another beneficial method is gentle kneading or circular motions around the joint to help alleviate muscle tension without aggravating the inflamed area. Additionally, using cold or warm compresses during massage can enhance the therapeutic effects. Cold therapy can help numb pain and reduce swelling, while warm therapy can promote relaxation and improve circulation.

Alternating between these two methods during a massage session may provide optimal relief. It is crucial to listen to one’s body during these sessions; if any technique causes increased pain or discomfort, it should be modified or avoided altogether.

Tips for Self-Massage at Home

Massage Technique	Benefits
Effleurage	Relaxes muscles and improves circulation
Kneading	Reduces muscle tension and promotes relaxation
Friction	Helps break down scar tissue and adhesions
Tapotement	Stimulates muscles and invigorates the body
Vibration	Relieves muscle tension and promotes relaxation

Self-massage can be an effective way to manage gout symptoms between professional therapy sessions. To begin, individuals should find a comfortable position that allows them to access the affected joint easily. Using gentle pressure with fingers or a soft massage tool, one can apply light strokes around the joint area to promote relaxation and circulation.

It is advisable to start with effleurage techniques before gradually incorporating more targeted pressure on surrounding muscles. In addition to manual techniques, individuals may benefit from incorporating essential oils known for their anti-inflammatory properties into their self-massage routine. Oils such as lavender or peppermint can be diluted with a carrier oil and gently massaged into the skin around the affected joint.

This not only enhances the massage experience but also provides additional relief through aromatherapy. Consistency is key; regular self-massage sessions can help maintain mobility and reduce discomfort over time.

Incorporating Gout Massage into a Holistic Treatment Plan

Integrating gout massage into a holistic treatment plan involves considering various lifestyle factors that contribute to overall health and well-being. Alongside massage therapy, individuals should focus on dietary modifications aimed at reducing uric acid levels. This includes increasing hydration by drinking plenty of water and limiting intake of purine-rich foods.

A balanced diet rich in fruits, vegetables, whole grains, and low-fat dairy products can support overall joint health. Moreover, engaging in regular physical activity tailored to individual capabilities can enhance joint function and reduce the frequency of gout attacks. Low-impact exercises such as swimming or cycling are often recommended as they minimize stress on the joints while promoting cardiovascular health.

By combining massage therapy with dietary changes and exercise, individuals can create a comprehensive approach to managing gout that addresses both immediate symptoms and long-term health goals. This holistic strategy not only alleviates pain but also empowers individuals to take control of their health journey.

Can Aspirin Worsen Gout Symptoms? Understanding the Connection

by Sanjay | Jan 30, 2025 | Gout, Over-the-Counter, Treatment

Aspirin, also known as acetylsalicylic acid, is a widely used medication for managing pain and inflammation. It belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs) and is commonly used to alleviate symptoms associated with conditions such as headaches, muscle aches, arthritis, and fever. Aspirin works by inhibiting the production of prostaglandins, which are hormone-like substances that play a key role in the body’s inflammatory response.

By reducing the levels of prostaglandins, aspirin helps to alleviate pain and decrease inflammation in the body. Moreover, low-dose aspirin is often prescribed for its blood-thinning properties, which can help prevent blood clots and reduce the risk of heart attack and stroke in individuals at high risk for cardiovascular events. This use of aspirin is particularly common in individuals with a history of heart disease or those who have undergone certain cardiac procedures.

The antiplatelet effects of low-dose aspirin make it a valuable tool in the management of cardiovascular health.

Key Takeaways

Aspirin can worsen gout symptoms by increasing uric acid levels in the body.
Aspirin is commonly used to manage pain and inflammation, but it can exacerbate gout symptoms.
Low dose aspirin is often recommended for heart health, but gout sufferers should be cautious due to potential risks.
Research and studies have shown a connection between aspirin and gout symptoms, highlighting the need for personalized advice from healthcare professionals.
Gout patients can explore alternative pain management strategies and lifestyle changes to support gout management, in consultation with a healthcare professional.

Low Dose Aspirin for Heart Health

Low-dose aspirin, typically defined as 81 milligrams per day, has been widely recommended for individuals at high risk of cardiovascular events. It is often prescribed to prevent blood clots from forming and causing blockages in the arteries, which can lead to heart attacks and strokes. The antiplatelet properties of low-dose aspirin make it an essential component of the treatment and prevention of cardiovascular diseases.

Furthermore, low-dose aspirin has been shown to be effective in reducing the risk of recurrent cardiovascular events in individuals who have previously experienced heart attacks or strokes. Its ability to inhibit platelet aggregation and reduce the formation of blood clots contributes to its role in maintaining heart health. However, it is important to note that the use of low-dose aspirin for heart health should always be discussed with a healthcare professional, as individual risk factors and medical history play a crucial role in determining its appropriateness for each patient.

Potential Risks of Aspirin for Gout Sufferers

While aspirin is beneficial for managing pain and inflammation in various conditions, its use in gout management has raised concerns due to its potential to worsen gout symptoms. Gout is a form of arthritis characterized by sudden and severe attacks of pain, swelling, and redness in the joints, often affecting the big toe. The underlying cause of gout is the accumulation of uric acid crystals in the joints, leading to inflammation and intense discomfort.

Aspirin can exacerbate gout symptoms by interfering with the excretion of uric acid from the body, potentially leading to higher levels of uric acid and an increased risk of gout attacks. Additionally, aspirin’s antiplatelet effects may further complicate gout management by impacting blood clotting mechanisms and potentially triggering gout flares. Therefore, individuals with gout are advised to exercise caution when using aspirin for pain relief or other purposes, as it may have adverse effects on their condition.

Research and Studies on Aspirin and Gout Symptoms

Research on the relationship between aspirin use and gout symptoms has yielded valuable insights into the potential impact of aspirin on individuals with gout. Studies have indicated that high doses of aspirin can indeed interfere with uric acid excretion, leading to an increased risk of gout attacks. Furthermore, the antiplatelet properties of aspirin have been associated with alterations in platelet function and potential implications for gout management.

In addition, research has highlighted the importance of considering alternative pain management strategies for individuals with gout who require relief from pain and inflammation without exacerbating their condition. By exploring the mechanisms through which aspirin may affect gout symptoms, researchers aim to provide evidence-based recommendations for healthcare professionals and patients alike.

Alternative Pain Management Strategies for Gout Patients

Given the potential risks associated with aspirin use in individuals with gout, alternative pain management strategies are essential for effectively addressing gout-related discomfort.

Non-aspirin NSAIDs such as ibuprofen and naproxen are commonly used to manage pain and inflammation in gout without the same concerns regarding uric acid levels and platelet function.

These medications can provide relief from gout symptoms while minimizing the risk of exacerbating the underlying condition.

Furthermore, corticosteroids and colchicine are alternative options for managing acute gout attacks, offering effective relief from pain and inflammation without the potential drawbacks associated with aspirin use. Lifestyle modifications, including dietary changes and weight management, also play a crucial role in gout management by addressing underlying factors contributing to gout flares.

Consulting a Healthcare Professional for Personalized Advice

Personalized Guidance for Effective Gout Management

Healthcare providers can assess each patient’s medical history, current medications, and specific needs to recommend the most appropriate approach to managing gout-related symptoms while minimizing potential risks.

Tailored Interventions for Unique Circumstances

Moreover, healthcare professionals can offer guidance on lifestyle modifications, medication adjustments, and other interventions tailored to each individual’s unique circumstances.

Informed Decision-Making for Optimal Gout Care

By seeking personalized advice from a healthcare professional, individuals with gout can make informed decisions regarding their pain management strategies and overall gout care.

Lifestyle Changes to Support Gout Management

In addition to considering medication options and pain management strategies, lifestyle changes play a pivotal role in supporting gout management. Dietary modifications aimed at reducing purine-rich foods, alcohol consumption, and excessive sugar intake can help lower uric acid levels and decrease the frequency of gout attacks. Maintaining a healthy weight through regular physical activity and balanced nutrition is also crucial for managing gout symptoms and reducing the risk of complications.

Furthermore, staying well-hydrated by consuming an adequate amount of water each day can support kidney function and promote the excretion of uric acid from the body. By adopting a holistic approach that encompasses lifestyle changes alongside appropriate medication management, individuals with gout can effectively manage their condition and minimize the impact of gout symptoms on their daily lives. In conclusion, while aspirin serves as a valuable tool for managing pain and inflammation in various conditions, its potential impact on gout symptoms warrants careful consideration.

Individuals with gout should be mindful of the potential risks associated with aspirin use and explore alternative pain management strategies under the guidance of a healthcare professional. By prioritizing personalized care, evidence-based interventions, and lifestyle modifications, individuals with gout can effectively manage their condition while minimizing the potential exacerbation of gout symptoms.

Strenuous Exercise Affects Gout

by Sanjay | Nov 20, 2024 | Excercise, Gout

How Does Strenuous Exercise Affect Gout?

Increased Uric Acid Production: During strenuous exercise, the body’s metabolic rate increases, leading to the production of more uric acid. This is because exercise can increase the breakdown of purines, which are then converted into uric acid (Kakutani-Hatayama et al., 2017, pp. 321–329).
Dehydration: Strenuous exercise can lead to dehydration, which reduces the body’s ability to excrete uric acid through the kidneys. When the body is dehydrated, the concentration of uric acid in the blood increases, which can lead to the formation of uric acid crystals (Kakutani-Hatayama et al., 2017, pp. 321–329; Poortmans, 1995, pp. 317–324).
Lactic Acid Production: Intense exercise can also lead to the production of lactic acid, which competes with uric acid for excretion by the kidneys. This competition can result in higher levels of uric acid in the blood (Kakutani-Hatayama et al., 2017, pp. 321–329).
Oxidative Stress: Exercise-induced oxidative stress can exacerbate inflammation in the body. The production of reactive oxygen species (ROS) during strenuous exercise can lead to cellular damage and inflammation, which may trigger a gout flare-up (Chevion et al., 2003, pp. 5119–5123; Liu et al., 1999, pp. E1083–E1091).
Muscle Damage: Strenuous exercise can cause muscle damage, leading to the release of proteins and other substances into the bloodstream. This can increase the body’s inflammatory response, potentially triggering a gout attack (Kakutani-Hatayama et al., 2017, pp. 321–329).

Organ Functions Involved

Kidneys

The kidneys play a crucial role in excreting uric acid from the body. During dehydration or when there is competition from lactic acid, the kidneys may not effectively remove uric acid, leading to its accumulation (Kakutani-Hatayama et al., 2017, pp. 321–329; Poortmans, 1995, pp. 317–324).

Filtration: Blood enters the kidneys through the renal arteries, where it is filtered in the glomeruli. Uric acid, along with other waste products, is filtered out of the blood.
Reabsorption: After filtration, some uric acid is reabsorbed back into the bloodstream in the renal tubules. This process is regulated by specific transporters, such as URAT1 and GLUT9.
Secretion: Uric acid that is not reabsorbed is secreted into the urine for excretion. This process is also regulated by transporters in the renal tubules.
Excretion: The final step is the excretion of uric acid in the urine. Adequate hydration is essential for maintaining urine flow and preventing the accumulation of uric acid.

Impact of Strenuous Exercise on Kidney Function

During strenuous exercise, the kidneys undergo several changes:

Reduced Blood Flow: Exercise can lead to a temporary reduction in renal blood flow, which can affect the kidneys’ ability to filter and excrete waste products, including uric acid (Poortmans & Vanderstraeten, 1994, pp. 419–437; Trejo et al., 2017, p. 17).
Increased Protein Excretion: Strenuous exercise can increase the excretion of proteins in the urine, a condition known as exercise-induced proteinuria (Poortmans & Vanderstraeten, 1994, pp. 419–437).
Transient Changes in Renal Function: Exercise can cause transient changes in renal function, such as decreased glomerular filtration rate (GFR) and altered electrolyte balance (Trejo et al., 2017, p. 17).

Liver

The liver is involved in the metabolism of purines. During intense exercise, the liver’s ability to process purines may be overwhelmed, leading to increased uric acid production (Kakutani-Hatayama et al., 2017, pp. 321–329).

Purine Metabolism: The liver is responsible for breaking down purines into uric acid. This process involves several enzymes, including xanthine oxidase, which converts hypoxanthine to xanthine and then to uric acid.
Uric Acid Production: The liver produces uric acid as a byproduct of purine metabolism. This uric acid is then released into the bloodstream, where it can be excreted by the kidneys.
Detoxification: The liver helps detoxify the body by converting harmful substances into less toxic forms. This includes the conversion of excess purines into uric acid for excretion.
Regulation of Blood Uric Acid Levels: The liver helps regulate blood uric acid levels by balancing the production and excretion of uric acid. This is crucial for preventing the accumulation of uric acid crystals in the joints.

Impact of Strenuous Exercise on Liver Function

During strenuous exercise, the liver undergoes several changes:

Increased Metabolic Demand: The liver’s metabolic demand increases during exercise, leading to increased production of uric acid.
Altered Blood Flow: Exercise can lead to a temporary reduction in blood flow to the liver, affecting its ability to metabolize purines and excrete uric acid.
Oxidative Stress: The liver is susceptible to oxidative stress during intense exercise, which can impair its function and exacerbate inflammation.

Muscles: Exercise-induced muscle damage can release substances that increase inflammation, contributing to a gout flare-up (Kakutani-Hatayama et al., 2017, pp. 321–329).

Managing Gout During Exercise

While strenuous exercise can potentially trigger a gout flare-up, it doesn’t mean that people with gout should avoid exercise altogether. Exercise is important for overall health and can help manage weight, which is a risk factor for gout. Here are some tips for managing gout during exercise:

Stay Hydrated: Drinking plenty of water before, during, and after exercise can help flush uric acid from the body and prevent dehydration (Kakutani-Hatayama et al., 2017, pp. 321–329).
Moderate Exercise Intensity: Engaging in moderate-intensity exercise rather than strenuous exercise can reduce the risk of a gout flare-up (Kakutani-Hatayama et al., 2017, pp. 321–329).
Monitor Uric Acid Levels: Regularly monitoring uric acid levels can help manage gout and prevent flare-ups (Kakutani-Hatayama et al., 2017, pp. 321–329).
Consult a Healthcare Provider: Before starting a new exercise regimen, it’s important to consult a healthcare provider, especially if you have gout or other health conditions (Kakutani-Hatayama et al., 2017, pp. 321–329).

Conclusion

Strenuous exercise can lead to a gout flare-up due to increased uric acid production, dehydration, competition for excretion with lactic acid, oxidative stress, and muscle damage. These factors can lead to the accumulation of uric acid in the blood and the formation of uric acid crystals in the joints, triggering inflammation and pain associated with gout. By managing hydration, moderating exercise intensity, and monitoring uric acid levels, individuals can reduce the risk of exercise-induced gout flare-ups and maintain a healthy lifestyle.

Bibliography

(more…)

Gout is Most Common in These Areas

by Sanjay | Nov 20, 2024 | Gout

To understand where gout is most common around the world and why, let’s break it down in a way that’s easy to grasp.

What is Gout?

Gout is a type of arthritis, which is a condition that causes pain and swelling in the joints. It happens when there is too much uric acid in the blood. Uric acid is a substance that forms when the body breaks down purines, which are found in certain foods and drinks. When there is too much uric acid, it can form sharp crystals in the joints, leading to the painful symptoms of gout.

Where is Gout Most Common?

Gout is found all over the world, but some areas have more cases than others. Here are some regions where gout is particularly common:

North America: In countries like the United States, gout is quite common. This is partly because of the diet and lifestyle, which often includes foods and drinks high in purines, like red meat and sugary beverages.
East Asia: Countries like China and Japan have seen an increase in gout cases. This rise is linked to changes in diet and lifestyle as these countries become more developed.
Pacific Islands: In places like New Zealand, especially among the Maori population, gout is more prevalent. This is due to genetic factors and dietary habits.
Europe: Some parts of Europe also report high cases of gout, particularly in countries with diets rich in meat and alcohol.

Why is Gout More Common in These Areas?

Several factors contribute to the high prevalence of gout in these regions:

Diet: A diet high in purines can lead to higher levels of uric acid. Foods like red meat, seafood, and sugary drinks are rich in purines. In many developed countries, these foods are consumed frequently, leading to more cases of gout.
Lifestyle: Sedentary lifestyles, where people do not get enough physical activity, can contribute to obesity, which is a risk factor for gout. Many people in developed countries have jobs that require sitting for long periods, and they may not exercise enough.
Genetics: Some populations have a genetic predisposition to gout. This means that they are more likely to develop the condition due to their genetic makeup. For example, the Maori people in New Zealand have a higher genetic risk for gout.
Obesity: Being overweight or obese increases the risk of developing gout. This is because more body fat can lead to higher levels of uric acid. In many developed countries, obesity rates are high, which correlates with higher gout cases.
Alcohol Consumption: Drinking alcohol, especially beer, can increase uric acid levels. In regions where alcohol consumption is high, there are often more cases of gout.
Age and Gender: Gout is more common in men than in women, and it often develops in middle age. However, after menopause, women’s risk increases. This pattern is seen globally.

How Can Gout Be Managed?

While gout can be painful, it is manageable with the right approach:

Dietary Changes: Reducing the intake of purine-rich foods can help lower uric acid levels. This means eating less red meat and seafood and avoiding sugary drinks and alcohol.
Weight Management: Maintaining a healthy weight through diet and exercise can reduce the risk of gout attacks.
Medication: There are medications available that can help lower uric acid levels and manage pain during gout attacks.
Hydration: Drinking plenty of water can help flush uric acid from the body.
Regular Check-Ups: Regular visits to a healthcare provider can help monitor uric acid levels and adjust treatment as needed.

Conclusion

Gout is a common condition that affects many people worldwide, particularly in regions with diets high in purines and sedentary lifestyles. Understanding the factors that contribute to gout can help in managing and preventing it. By making lifestyle changes and seeking medical advice, individuals can reduce their risk of gout and manage its symptoms effectively.

Bibliography:

Ahn, J. (2023). Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. Journal of Rheumatic Diseases, 30, 88–98.

Al-Allaf, A., & Rheumatologist, C. (1970). Gout: evidence based update with new therapeutic strategies. Sudan Medical Journal.

Alderman, M. (2007). Uric Acid , and Cardiovascular Disease.

AlQahtani, A., Alim, B. M., Almudhaibery, F. S., Mulafikh, D., Almutairi, S., Almohanna, S., & Alfawwaz, F. S. (2022). The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study. American Journal of Rhinology & Allergy, 36, 423–431.

Araujo Dantas, A. B., Gonçalves, F., Martins, A., Santos Alves, G. Â., Stechman-Neto, J., Corrêa, C., Santos, R., Nascimento, W., Araújo, C. M., & Taveira, K. V. M. (2023). Worldwide prevalence and associated risk factors of obstructive sleep apnea: a meta-analysis and meta-regression. Sleep and Breathing, 27, 2083–2109.

Barbadoro, P., Luciani, A., Ciotti, M., D’Errico, M., & Group, O. B. O. T. A. W. C. (2020). Two-Source Capture-Recapture Method to Estimate the Incidence of Acute Flaccid Paralysis in the Marches Region (Italy). International Journal of Environmental Research and Public Health, 17.

Bardin, T., & Richette, P. (2017). Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine, 15.

Barskova, V. G., & Mukagova, M. V. (2011). Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Modern Rheumatology Journal, 5, 39–43.

Bozio, P. M. C., Ujamaa, M. D., Dawood, M. F. S., Chai, M. M. S., Kirley, M. P. D., Alden, M. N. B., Austin, M. E., Desiato, M. J., Yousey-Hindes, M. K., EmilyFawcett, M., KyleP.Openo, M., MayaMonroe, M., PatriciaA.Ryan, M., Science Anna Falkowski, M., Kim, M. S., eld, M. R. L., McMahon, M. M., Angeles, M. K., Khanlian, M. S., … Garg, M. S. (2023). 2614. Trends in characteristics of influenza-associated hospitalizations among pregnant women, FluSurv-NET 2015-2016 through 2022-2023 seasons. Open Forum Infectious Diseases, 10.

Broström, A., Alimoradi, Z., Lind, J., Ulander, M., Lundin, F., & Pakpour, A. (2023). Worldwide estimation of restless legs syndrome: a systematic review and meta‐analysis of prevalence in the general adult population. Journal of Sleep Research, 32.

Buckley, H. (2011). Epidemiology of Gout: Perspectives from the Past. Current Rheumatology Reviews, 7, 106–113.

Celermajer, D. (2017). Eisenmenger syndrome: a rare malady that continues to fascinate. European Heart Journal, 38, 2068–2069.

Cheremushkina, E., Eliseev, M., Severinova, M., & Zhelyabina, O. (2023). Sonography as method for diagnosing gout at preclinical stage (preliminary data from pilot study). Medical Alphabet.

Chiarotti, F., & Venerosi, A. (2020). Epidemiology of Autism Spectrum Disorders: A Review of Worldwide Prevalence Estimates Since 2014. Brain Science, 10.

Chikina, M., Ilyinykh, E., & Eliseev, M. (2020). Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence). Modern Rheumatology Journal, 14, 70–75.

Chua, C., & Thong, B. (2021). Inflammatory Arthritis Among Military Servicemen From a Rheumatology Center in Singapore. Military Medicine.

Dehlin, M., Drivelegka, P., Sigurdardottir, V., Svärd, A., & Jacobsson, L. (2016a). Incidence and prevalence of gout in Western Sweden. Arthritis Research & Therapy, 18.

Dehlin, M., Drivelegka, P., Sigurdardottir, V., Svärd, A., & Jacobsson, L. (2016b). THU0522 Increasing Incidence of Gout in Western Sweden – A Register Study. Annals of the Rheumatic Diseases, 75, 381–381.

Denova, L. D. (2023). The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity. KIDNEYS.

Donzelli, A., Battaggia, A., & Schivalocchi, A. (2017). Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies. Osteoporosis International, 28, 2739–2740.

Dp, M. (1992). [Changes in the epidemiology, symptomatology and prognosis of gout]. Versicherungsmedizin / Herausgegeben von Verband Der Lebensversicherungs-Unternehmen e.V. Und Verband Der Privaten Krankenversicherung e.V, 44, 10–13.

Egami, T., & Ryu, C. W. (2023). Origin of medium-range atomic correlation in simple liquids: Density wave theory. AIP Advances.

Fernández‐Cruz, A., Menárguez, M. C., Muñoz, P., Pedromingo, M., Peláez, T., Solís, J., Rodrı́guez-Créixems, M., Bouza, E., & group. (2015). The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. European Journal of Clinical Microbiology and Infectious Diseases, 34, 1543–1549.

Freeman, E. (1902). THREE CASES OF CEREBRO-SPINAL FEVER TREATED WITH ANTIPYRIN. British Medical Journal, 1, 1262–1263.

Furuichi, K., Shimizu, M., Yuzawa, Y., Hara, A., Toyama, T., Kitamura, H., Suzuki, Y., Sato, H., Uesugi, N., Ubara, Y., Hoshino, J., Hisano, S., Ueda, Y., Nishi, S., Yokoyama, H., Nishino, T., Kohagura, K., Ogawa, D., Mise, K., … Nephros. (2018). Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis. Clinical and Experimental Nephrology, 22, 629–637.

Geedigunta, V., Khan, Z., Bachan, M., Latef, S., Eshak, D., & Dosala, S. (2022). A Unique Case of Pneumocystis Jirovecii (PCP) Pneumonia in HIV- Uninfected, COVID -19 Positive Patient. C61. BREAKING THE MOLD.

Gelsomino, M., & Tamborrini, G. (2014). [Treatment resistant polyarthritis]. Praxis, 103 14, 841–844.

Gill, D., Daniel, R., Halpern, L., & Southerland, J. (2016). A Giant Submandibular Sialolith in the Setting of Chronic Sialodenitis : A Case Report and Literature Review.

Giorgi, A. D., Fabbian, F., Pala, M., Tiseo, R., Parisi, C., Misurati, E., & Manfredini, R. (2015). Uric acid: friend or foe? Uric acid and cognitive function “Gout kills more wise men than simple”. European Review for Medical and Pharmacological Sciences, 19 4, 640–646.

Guizzardi, G., & Guarino, N. (2023). Semantics, Ontology and Explanation. arXiv.Org, abs/2304.11124.

Gupta, R. S., Koteci, A., Morgan, A., George, P., & Quint, J. (2023). Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respiratory Research, 10.

Gupta, S., Yui, J., Xu, D., Fitzhugh, C., Clark, C., Siddiqui, S., Conrey, A. K., Kato, G., & Minniti, C. (2015). Gout and sickle cell disease: not all pain is sickle cell pain. British Journal of Haematology, 171.

Hameed, M., Turkiewicz, A., Englund, M., Jacobsson, L., & Kapetanovic, M. (2019). Prevalence and incidence of non-gout crystal arthropathy in southern Sweden. Arthritis Research & Therapy, 21.

Hancuh, M., Walldorf, J., Minta, A. A., Tévi-Bénissan, C., Christian, K., Nedelec, Y., Heitzinger, K., Mikoleit, M., Tiffany, A., Bentsi-Enchill, A., & Breakwell, L. (2023). Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction — Worldwide, 2018–2022. MMWR. Morbidity and Mortality Weekly Report, 72, 171–176.

Hazlina, N. H. N., Norhayati, M. N., Bahari, I. S., & Arif, N. A. N. M. (2022). Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta-analysis. BMJ Open, 12.

Hor, J. Y., Asgari, N., Nakashima, I., Broadley, S., Leite, M., Kissani, N., Jacob, A., Marignier, R., Weinshenker, B., Paul, F., Pittock, S., Palace, J., Wingerchuk, D., Behne, J., Yeaman, M., & Fujihara, K. (2020). Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 11.

Hor, J. Y., & Fujihara, K. (2023). Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Frontiers in Neurology, 14.

Huang, J., Chan, W. C., Ngai, C., Lok, V., Zhang, L., Lucero‐Prisno, D., Xu, W., Zheng, Z., Elcarte, E., Withers, M., Wong, M. C. S., & A, O. B. O. N. G. H. R. G. O. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14.

Ijms, E. B. (2022). Abstracts of the Medical Academical Conference of Piauí (COMAPI) 2021. International Journal of Medical Studies.

Iqbal, U., Siddiqui, H. U., Anwar, H., Chaudhary, A., & Quadri, A. (2017). Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. Journal of Investigative Medicine High Impact Case Reports, 5.

Jiang, L., Chen, S., Wu, Y., Zhou, D., & Duan, L. (2023). Prediction of coronary heart disease in gout patients using machine learning models. Mathematical Biosciences and Engineering : MBE, 20 3, 4574–4591.

Johnson, G. (1873). Lectures on the Pathology, Diagnosis, and Treatment of Bright’s Disease. British Medical Journal, 1, 725–726.

Kancherla, V. (2023). Neural tube defects: a review of global prevalence, causes, and primary prevention. Child’s Nervous System, 1–8.

Kawamura, Y., Nakaoka, H., Nakayama, A., Okada, Y., Yamamoto, K., Ooyama, H., Stibůrková, B., Merriman, T., Nakatochi, M., Wakai, K., Kubo, M., Ichida, K., Shinomiya, N., & Matsuo, H. (2019). OP0047 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED NOVEL LOCI ASSOCIATED WITH THE PROGRESSION FROM ASYMPTOMATIC HYPERURICEMIA TO GOUT. Oral Presentations, 78, 94–95.

Klerk, E., Heijde, D. M., Tempel, H., & Linden, S. (1999). Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. Journal of Rheumatology, 26 12, 2635–2641.

Knowledge, Attitude and Practices Assessment of the Gout Patients Residing in Lahore, Pakistan. (2022). Pakistan Journal of Medicine and Dentistry.

Kodio, B., Pamanta, I., Sylla, C., Kayentao, K., Dolo, H., & Cissé, I. (2015). Step wise approach of gout in the rheumatology ward of Point-G University Teaching Hospital of Bamako, Mali. 3, 22–26.

Koto, R., Nakajima, A., Horiuchi, H., & Yamanaka, H. (2019). FRI0678 PREVALENCE, PATIENT CHARACTERISTICS, AND TREATMENT OF GOUT AND ASYMPTOMATIC HYPERURICEMIA IN JAPAN: CROSS-SECTIONAL STUDY OF A HEALTH INSURANCE CLAIMS DATABASE. Epidemiology, Risk Factors for Disease or Disease Progression, 78, 1037–1037.

Kuo, C., Grainge, M., See, L., Yu, K.-H., Luo, S., Zhang, W., & Doherty, M. (2015). Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Research & Therapy, 17.

Lee, E., Knox, C., & Phillips, E. (2023). Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatology.

Lee, J., Lee, J. S., Chung, M., Ahn, J., Choi, H., Hong, S.-J., Yoon, C., Kim, S.-H., Jeong, K.-H., Kim, J.-W., Kim, B.-Y., Shin, J., Kim, W., Kim, S., Kim, H.-J., Song, J.-S., Jun, J.-B., Park, H.-A., Chae, S., … Kim, H. A. (2023). Korean guidelines for the management of gout. Journal of Rheumatic Diseases, 30, 141–150.

Lerma, O., Kosheleva, O., & Kreinovich, V. (2014). A Simple Geometric Model Provides a Possible Quantitative Explanation of the Advantages of Immediate Feedback in Student Learning.

Li, F., Qin, W., Zhu, M., & Jia, J. (2021). Model-Based Projection of Dementia Prevalence in China and Worldwide: 2020-2050. Journal of Alzheimer’s Disease.

Li, H., Nie, D., Wang, S., Li, D., & Liu, C.-H. (2021). Clinical value of turbidity-elimination gout soup combined with external application of traditional chinese medicine to improve the pain and the volume of tophi in patients with gout. Food Science and Technology International.

Maggioni, A., Rossi, E., Cinconze, E., Roggeri, D., Roggeri, A., Fabbri, G., Rosa, M., & Arno Cardiovascular Observatory. (2013). Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting. Cardiovascular Drugs and Therapy, 27, 333–340.

Martínez-Martínez, M., Román-Acosta, S., Alvarez-Reyes, J., Oros-Ovalle, C., & Abud-Mendoza, C. (2013). [Calciphylaxis, renal failure and gout. A patient with hyperuricemia as a risk factor for death]. Revista Medica Del Instituto Mexicano Del Seguro Social, 51 2, 218–221.

Mattiuzzi, C., & Lippi, G. (2019). Recent updates on worldwide gout epidemiology. Clinical Rheumatology, 39, 1061–1063.

Mémin, Y., Monville, C., & Ryckewaert, A. (1978). [Articular chondrocalcinosis after 80 years of age]. Revue Du Rhumatisme et Des Maladies Osteo-Articulaires, 45 2, 77–82.

Mertz, D. (1992). [Changes in the epidemiology, symptomatology and prognosis of gout]. Versicherungsmedizin, 44 1, 10–13.

Mittal, G., Oncologist, S., Manjunath, S., Naik, B. N., Deb, S., & Pathology, O. (2020). Clinico-pathological co-relation using various immuno-histochemistry markers likeER, PR, HER-2 NEU, CK5/6, EGFR, KI-67 in carcinoma breast. 5, 30–34.

Moorthie, S., Blencowe, H., Darlison, M. W., Lawn, J., Morris, J., Modell, B., Bittles, A., Blencowe, H., Christianson, A., Cousens, S., Darlison, M. W., Gibbons, S., Hamamy, H., Khoshnood, B., Howson, C., Lawn, J., Mastroiacovo, P., Modell, B., Moorthie, S., … Yunnis, K. A. (2018). Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. Journal of Community Genetics, 9, 387–396.

Nicholson, P., Saunsbury, E., D’Angelo, S., Churchill, D., & Walker-Bone, K. (2018). Prevalence of and risk factors for gout in HIV-positive adults: A case–control study. International Journal of STD and AIDS, 30, 249–255.

Nkeck, J., Singwé-Ngandeu, M., Moor, V., Chedjou, J.-P., Doualla, M., & Mbacham, W. (2017). Evaluation of Oxidative Status of Patients with Gout Attack in a Cameroonian Urban Hospital. Open Journal of Rheumatology and Autoimmune Diseases, 07, 111–119.

Parchami-Araghi, A., Bohle, M., Rao, S., & Schiele, B. (2024). Good Teachers Explain: Explanation-Enhanced Knowledge Distillation. arXiv.Org, abs/2402.03119.

Pillinger, M., & Abeles, A. (2010). Such Sweet Sorrow: Fructose and the Incidence of Gout. Current Rheumatology Reports, 12, 77–79.

Pirog, E., Lloveras, B., Molijn, A., Tous, S., Guimerà, N., Alejo, M., Clavero, O., Klaustermeier, J., Jenkins, D., Quint, W., Bosch, F., Alemany, L., & Sanjosé, S. (2014). HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathology, 27, 1559–1567.

Pukdee, R., Sam, D., Kolter, J. Z., Balcan, M.-F., & Ravikumar, P. (2023). Learning with Explanation Constraints. Neural Information Processing Systems, abs/2303.14496.

Rachina, S., Kozlov, R., Kurkova, A., Portnyagina, U., Palyutin, S., Khokhlov, A., Reshetko, O., Zhuravleva, M., Palagin, I., & Project, O. B. O. R. W. G. O. T. (2022). Antimicrobial Dispensing Practice in Community Pharmacies in Russia during the COVID-19 Pandemic. Antibiotics, 11.

Rana, A., D’Addio, R. M., Manzato, M., & Bridge, D. (2022). Extended recommendation-by-explanation. User Modeling and User-Adapted Interaction, 32, 91–131.

Ransome, A. (1883). Progressive Pernicious Anæmia: A Case, with Remarks*. British Medical Journal, 1, 1112–1113.

Redondo-Rodriguez, R., Mena-Vázquez, N., Cabezas-Lucena, A. M., Manrique-Arija, S., Mucientes, A., & Fernández-Nebro, A. (2022). Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Journal of Clinical Medicine, 11.

Rees, F., Doherty, M., Grainge, M., Lanyon, P., & Zhang, W. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology, 56, 1945–1961.

Roman, Y. M., Tiirikainen, M., & Prom-Wormley, E. (2020). The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clinical Rheumatology, 39, 2387–2392.

Russell, E., & Checa, A. (2013). Potential pitfalls in the diagnosis of crystal-induced arthritis and in the sonographic measurement of hyaline cartilage due to the presence of joint effusion. Journal of Clinical Rheumatology, 19 2, 98–100.

Saunsbury, E., Mahendran, P., Youssef, E., Churchill, D., Roddy, E., Packham, J., Obrenovic, K., & Ledingham, J. (2014). PREVALENCE OF AND RISK FACTORS FOR GOUT IN THE HIV-INFECTED POPULATION.

Sigurdsson, E. (2013). Up and running: An underutilized prescription in primary care. Scandinavian Journal of Primary Health Care, 31, 1–2.

Singh, G., Lingala, B., & Mithal, A. (2019a). Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology.

Singh, G., Lingala, B., & Mithal, A. (2019b). SAT0405 GOUT AND HYPERURICEMIA IN THE US: PREVALENCE AND TRENDS. Saturday, 15 June 2019, 78, 1290–1290.

Sparks, S., Vang, P. C., Peterman, B., Moua, M., & Phillips, L. (2014). Commentary: Utilizing Community-Engaged Approaches to Investigate and Address Hmong Women’s Cancer Disparities. Hmong Studies Journal, 15, 1–18.

Sriboonchitta, S., & Kreinovich, V. (2018). Why Are FGM Copulas Successful? A Simple Explanation. Advances in Fuzzy Systems, 2018, 5872195:1-5872195:5.

Teng, M., Ng, C., Huang, D. Q., Chan, K., Tan, D. J. H., Lim, W., Yang, J. D., Tan, E., & Muthiah, M. (2022). Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 29, S32–S42.

The, W. C. O. T. R. O. C. H. A. (2023). Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. Biomedical and Environmental Sciences : BES, 36 8, 669–701.

Ting, K., Gill, T., Keen, H., Tucker, G. R., & Hill, C. (2016). Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study. Internal Medicine Journal (Print), 46.

Urban, M. (2016). 17. Motivation by formally analyzable terms in a typological perspective: An assessment of the variation and steps towards explanation.

Utkin, L., Meldo, A., Kovalev, M., & Kasimov, E. (2020). A Simple General Algorithm for the Diagnosis Explanation of Computer-Aided Diagnosis Systems in Terms of Natural Language Primitives. System Configuration Management, 202–205.

Vinotha, T. (2015). Association of High Serum Uric Acid Levels in Chronic Liver Disease.

Watson, C. (1905). REASONS FOR ABANDONING THE URIC ACID THEORY OF GOUT. British Medical Journal, 1, 127–129.

West, S. (1911). A Clinical Lecture ON GRANULAR KIDNEY AND ITS SURPRISES. British Medical Journal, 1, 1099–1101.

Wright, C. (1975). An explanation for some aspects of the behaviour of congested road traffic in terms of a simple model. Transportation Research, 9, 267–273.

Wright, S., Chapman, P., Frampton, C., O’Donnell, J., & Raja, R. (2017). The Journal of Rheumatology Management of Gout in a Hospital Setting : A Lost Opportunity and Lisa Stamp.

Xu, H., Qin, H., Hua, Y., & Dalbeth, N. (2023). Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research. Annals of the Rheumatic Diseases, 82, 1511–1515.

Yi-nu, M., & Xin, O. (2009). Progress of High Methylation On Cerical Cancer Related Gene Promoter. Progress in Modern Biomedicine.

Yun-fe, H. (2015). Investigation of the abnormal of serum carbohydrate antigen 724 level in patients with gout. Chinese Journal of Health Laboratory Technology.

Yung-Chen, Lin, C.-S., Hong, C.-F., Lee, D. J., Sun, C., & Lin, H.-H. (2019). Design of a Clinical Decision Support System for Predicting Erectile Dysfunction in Men Using NHIRD Dataset. IEEE Journal of Biomedical and Health Informatics, 23, 2127–2137.

Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M., Saxena, S., Yusuf, A., Shih, A., & Elsabbagh, M. (2022). Global prevalence of autism: A systematic review update. Autism Research, 15, 778–790.

Zhang, J., Jin, C., Ma, B., Sun, H., Chen, Y., Zhong, Y., Han, C., Liu, T., & Li, Y. (2023). Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study. RMD Open, 9.

Ziegler, A., Ladman, B., Dunn, P., Schneider, A., Davison, S., Miller, P., Lu, H., Weinstock, D., Salem, M., Eckroade, R., & Gelb, J. (2002). Nephropathogenic Infectious Bronchitis in Pennsylvania Chickens 1997–2000. Avian Diseases, 46, 847–858.

Zimmerman, H., Bhagwat, M., Laranger, R., Padnick-Silver, L., & LaMoreaux, B. (2023). AB1240 PERCEPTIONS OF GOUT AND ITS MANAGEMENT PATTERNS: FINDINGS FROM SURVEY AND STRUCTURED INTERVIEWS WITH PRIMARY CARE PHYSICIANS AND RHEUMATOLOGISTS. Annals of the Rheumatic Diseases.

Zobbe, K., Prieto-Alhambra, D., Cordtz, R., Højgaard, P., Hindrup, J. S., Kristensen, L., & Dreyer, L. (2019). Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology.

Understanding Allergic Reactions to Allopurinol and Alternative Medications for Gout Management

by Sanjay | Oct 12, 2024 | Gout, Prescription, Treatment

gout Allopurinol is a commonly prescribed medication for the treatment of gout, a form of arthritis characterized by severe pain, redness, and tenderness in joints. Despite its efficacy, allopurinol can cause allergic reactions in some individuals. This blog will explore the types of people who may have an allergic reaction to allopurinol and discuss alternative medications that can be used to manage gout.

Who is at Risk for Allergic Reactions to Allopurinol?

1. Genetically Susceptible Populations

Certain genetic factors can predispose individuals to allergic reactions to allopurinol. One of the most significant genetic markers is the presence of the HLA-B*5801 allele. This allele is particularly prevalent in specific ethnic groups, including Han Chinese, Thai, and Korean populations. Individuals with this genetic marker are at a higher risk of developing severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when taking allopurinol (Greenberger, 2012, pp. 103–107; Stamp & Barclay, 2018, pp. i35–i41).

2. Patients with Chronic Kidney Disease

Chronic kidney disease (CKD) can increase the risk of allopurinol hypersensitivity syndrome (AHS). The impaired renal function in CKD patients can lead to the accumulation of allopurinol and its metabolites, increasing the likelihood of adverse reactions. Therefore, patients with CKD should be closely monitored when prescribed allopurinol, and alternative treatments should be considered if necessary (Stamp & Barclay, 2018, pp. i35–i41).

3. Individuals with a History of Drug Allergies

Patients with a history of allergic reactions to other medications are more likely to experience an allergic reaction to allopurinol. This includes individuals who have had previous reactions to drugs such as antibiotics, anticonvulsants, and nonsteroidal anti-inflammatory drugs (NSAIDs). A thorough medical history should be taken to identify any potential risks before prescribing allopurinol (Greenberger, 2012, pp. 103–107, 2019, pp. 474–479).

4. Patients with Specific Comorbidities

Certain comorbidities can increase the risk of allergic reactions to allopurinol. For example, individuals with human immunodeficiency virus (HIV) infection, chronic lymphocytic leukemia, and other immunocompromised states are at a higher risk of drug hypersensitivity reactions. These patients should be carefully evaluated before initiating allopurinol therapy (Greenberger, 2012, pp. 103–107, 2019, pp. 474–479).

5. Elderly Patients

Elderly patients are generally more susceptible to adverse drug reactions due to age-related changes in drug metabolism and excretion. The risk of allopurinol hypersensitivity may be higher in this population, necessitating careful dose adjustments and monitoring (Mumoli et al., 2011, pp. 709–710).

Alternative Medications for Gout Management

For individuals who cannot tolerate allopurinol due to allergic reactions, several alternative medications can be used to manage gout effectively. These alternatives include febuxostat, probenecid, and pegloticase, among others.

1. Febuxostat

Febuxostat is a xanthine oxidase inhibitor, similar to allopurinol, but with a different chemical structure. It is an effective alternative for patients who are allergic to allopurinol or have not achieved adequate uric acid control with allopurinol. Febuxostat has been shown to be effective in reducing serum uric acid levels and preventing gout flares. It is particularly useful for patients with renal impairment, as it does not require dose adjustments based on renal function (Bardin et al., 2016, pp. 314–317; Ильиных et al., 2017, pp. 83–88).

Efficacy and Safety

Clinical trials have demonstrated that febuxostat is as effective, if not more so, than allopurinol in lowering serum uric acid levels. It has also been associated with a lower risk of severe cutaneous adverse reactions compared to allopurinol. However, febuxostat should be used with caution in patients with cardiovascular disease, as some studies have suggested an increased risk of cardiovascular events with its use (Bardin et al., 2016, pp. 314–317; Ильиных et al., 2017, pp. 83–88).

2. Probenecid

Probenecid is a uricosuric agent that increases the excretion of uric acid in the urine. It is an effective alternative for patients who cannot tolerate xanthine oxidase inhibitors like allopurinol and febuxostat. Probenecid is particularly useful for patients with normal renal function and those who do not have a history of kidney stones (Sivordova et al., 2021).

Efficacy and Safety

Probenecid has been shown to be effective in reducing serum uric acid levels and preventing gout flares. However, it is not suitable for patients with renal impairment or a history of uric acid kidney stones, as it can increase the risk of stone formation. Additionally, probenecid can interact with other medications, so a thorough review of the patient’s medication list is necessary before initiating therapy(Sivordova et al., 2021).

3. Pegloticase

Pegloticase is a recombinant uricase enzyme that converts uric acid to allantoin, a more soluble and easily excreted compound. It is used for the treatment of chronic gout in patients who have not responded to conventional therapies. Pegloticase is administered intravenously and is typically reserved for patients with severe, refractory gout (Sivordova et al., 2021).

Efficacy and Safety

Pegloticase has been shown to be highly effective in reducing serum uric acid levels and resolving tophi in patients with chronic gout. However, it is associated with a risk of infusion reactions and the development of anti-pegloticase antibodies, which can reduce its efficacy over time. Patients receiving pegloticase should be closely monitored for signs of infusion reactions and antibody development (Sivordova et al., 2021).

4. Lesinurad

Lesinurad is a selective uric acid reabsorption inhibitor that works by inhibiting the URAT1 transporter in the kidneys, thereby increasing the excretion of uric acid. It is used in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout. Lesinurad is an option for patients who require additional uric acid-lowering therapy beyond what can be achieved with a xanthine oxidase inhibitor alone (Sivordova et al., 2021).

Efficacy and Safety

Lesinurad has been shown to be effective in combination with allopurinol or febuxostat in reducing serum uric acid levels. However, it is associated with a risk of renal adverse events, including acute renal failure, particularly when used as monotherapy. Therefore, lesinurad should always be used in combination with a xanthine oxidase inhibitor and with close monitoring of renal function(Sivordova et al., 2021).

5. Colchicine

Colchicine is an anti-inflammatory medication that is used to treat acute gout flares and to prevent recurrent flares. While it does not lower serum uric acid levels, it is an important adjunctive therapy for managing the inflammatory component of gout. Colchicine can be used in combination with uric acid-lowering therapies to provide comprehensive gout management(Sivordova et al., 2021).

Efficacy and Safety

Colchicine is effective in reducing the pain and inflammation associated with acute gout flares. It is also used at low doses for flare prophylaxis. However, colchicine can cause gastrointestinal side effects, such as diarrhea and abdominal pain, and should be used with caution in patients with renal or hepatic impairment. Drug interactions should also be considered, as colchicine can interact with several other medications (Sivordova et al., 2021).

Conclusion

Allopurinol is a widely used and effective medication for the management of gout, but it can cause allergic reactions in certain individuals. Populations at higher risk for allergic reactions to allopurinol include those with specific genetic markers, chronic kidney disease, a history of drug allergies, certain comorbidities, and elderly patients. For these individuals, alternative medications such as febuxostat, probenecid, pegloticase, lesinurad, and colchicine can be used to manage gout effectively.

It is essential for healthcare providers to carefully evaluate each patient’s risk factors and medical history before prescribing allopurinol or its alternatives. Close monitoring and patient education are crucial to ensure the safe and effective management of gout. By understanding the risks and benefits of each treatment option, healthcare providers can tailor therapy to meet the individual needs of their patients, improving outcomes and quality of life for those living with gout.

References

Abdurrahman, Z., Kastner, M., Wurman, C., Harada, L., Bantock, L., Cruickshank, H., & Waserman, S. (2011). Experiencing a first food allergic reaction: a survey of parent and caregiver perspectives. Allergy, Asthma & Clinical Immunology, 9, 18–18.

Adamcová, M., Šturdík, I., Koller, T., & Payer, J. (2016). [DRESS syndrome]. Vnitrni Lekarstvi, 62 4, 334–337.

Al-kuraishy, H., Al-Gareeb, A., Al-Niemi, M., Aljowaie, R. M., Almutairi, S., Alexiou, A., & Batiha, G. (2022). The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19. Inflammation, 45, 1651–1667.

Anonymous. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021. MMWR. Morbidity and Mortality Weekly Report, 70, 125–129.

Árnadóttir, M. (2014). Febuxostat in adenosine phosphoribosyltransferase deficiency. American Journal of Kidney Diseases, 64 2, 316.

Balakirski, G., & Merk, H. (2017). Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. Cutaneous and Ocular Toxicology, 36, 307–316.

Bardin, T., Chalès, G., Pascart, T., Flipo, R., Ea, H. K., Roujeau, J., Delayen, A., & Clerson, P. (2016). Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint, Bone, Spine : Revue Du Rhumatisme, 83 3, 314–317.

Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., & Zhao, B. (2022). Allergic Reactions After the Administration of COVID-19 Vaccines. Frontiers in Public Health, 10.

Blumenthal, K., Robinson, L., Camargo, C., Shenoy, E., Banerji, A., Landman, A., & Wickner, P. G. (2021). Acute Allergic Reactions to mRNA COVID-19 Vaccines. Journal of the American Medical Association (JAMA).

Brinker, A. (2009). Allopurinol and the role of uric acid in hypertension. Journal of the American Medical Association (JAMA), 301 3, 270; author reply 270-1.

Careta, M. F., Delgado, L., & Patriota, R. (2015). Report of Allergic Reaction After Application of Botulinum Toxin. Aesthetic Surgery Journal, 35 5, NP102-5.

Cash, J. C., & Bradbury-Golas, K. (2019). Allergic Rhinitis. Canadian Family Practice Guidelines.

Chu, D., Abrams, E., Golden, D., Blumenthal, K., Wolfson, A. R., Stone, C., Krantz, M., Shaker, M., & Greenhawt, M. (2022). Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis. JAMA Internal Medicine.

Copaescu, A., & Trublano, J. A. (2022). The assessment of severe cutaneous adverse drug reactions. Australian Prescriber, 45, 43–48.

Earll, J., & Saavedra, M. (1983). Oxipurinol therapy in allopurinol-allergic patients. American Family Physician, 28 5, 147–148.

Fam, A. (2001). Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Current Rheumatology Reports, 3, 29–35.

Fine, P., Savrinski, B., & Millodot, M. (2003). Contact lens management of a case of Stevens-Johnson syndrome: a case report. Optometry, 74 10, 659–664.

Fontana, R., Li, Y.-J., Phillips, E., Saeed, N., Barnhart, H., Kleiner, D., & Hoofnagle, J. (2021). Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver International (Print), 41, 1884–1893.

Gb, E. (2020). The Role of Uric Acid Metabolism in Anaphylaxis: the Effect of Allopurinol on Allergic Reactions to Peanut in Peanut Allergic Adults.

Gede, N., Putra, J., Ganesha, R., Ngurah, G., & Dermawan, P. (2023). Identification and treatment of identification and treatment of erythema multiforme induced by allopurinol. Interdental Jurnal Kedokteran Gigi (IJKG).

Godinho, M., Aguinaga, F., Grynszpan, R., Lima, V. M., Azulay, D., Cuzzi, T., Ramos‐e‐Silva, M., & Manela‐Azulay, M. (2015). Granulomatous reaction to red tattoo pigment treated with allopurinol. Journal of Cosmetic Dermatology, 14.

Greenberger, P. (2012). Chapter 30: Drug allergy. Allergy and Asthma Proceedings, 33 Suppl 1, 103–107.

Greenberger, P. (2019). Drug allergy. Allergy and Asthma Proceedings, 40 6, 474–479.

Han, S., Sun, L., He, F., & Che, H. (2017). Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells. Scientific Reports, 7.

Hui-Chen, & Zhang, Q. (2010). The Possible Pathogenesis and Clinic Treatment of Heavy Drug Eruption Caused by Allopurinol. International Medicine and Health Guidance News, 16, 2248–2250.

Kim, M. S., Youn, S., Na, C., & Shin, B. (2015). Allergic reaction to hyaluronidase use after hyaluronic acid filler injection. Journal of Cosmetic & Laser Therapy, 17, 283–285.

Kim, Y.-Y., Je, I., Kim, M. J., Kang, B., Choi, Y.-A., Baek, M., Lee, B., Choi, J. K., Park, H.-R., Shin, T., Lee, S., Yoon, S.-B., Lee, S.-R., Khang, D., & Kim, S.-H. (2016). 2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the FcεRI signaling pathway. Acta Pharmacologica Sinica, 38, 90–99.

Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., Bauer, A., Merk, H., Rabe, U., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., … Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo Journal International, 30, 51–55.

Kounis, N., Koniari, I., Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S., Gogos, C., Kouni, S., Kounis, G., Calogiuri, G., & Hung, M.-Y. (2021). Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines, 9.

Kumar, A., & Azmi, W. (2014). Phytomedicine: A novel alternative for treatment of gout.

Kumar, M., Duraisamy, K., & Chow, B. (2021). Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2). Cells, 10.

Kyung, S., Cho, Y., Kim, Y. J., Park, J.-W., Jeong, S., Jae-Lee, Sung, Y. M., & Lee, S. (2011). A Paragonimiasis Patient with Allergic Reaction to Praziquantel and Resistance to Triclabendazole: Successful Treatment after Desensitization to Praziquantel. Korean Journal of Parasitology, 49, 73–77.

Latalski, M., Walczyk, A., Fatyga, M., Rutz, E., Szponder, T., Bielecki, T., & Danielewicz, A. (2019). Allergic reaction to platelet-rich plasma (PRP). Medicine, 98.

Lockard, O., Harmon, C., Nolph, K., & Irvin, W. (1976). Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Annals of Internal Medicine, 85 3, 333–335.

Luxi, N., Giovanazzi, A., Arcolaci, A., Bonadonna, P., Crivellaro, M., Cutroneo, P., Ferrajolo, C., Furci, F., Guidolin, L., Moretti, U., Olivieri, E., Petrelli, G., Zanoni, G., Senna, G., & Trifirò, G. (2022). Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs, 36, 443–458.

Macaulay, S., Bayliff, C., & Mehta, S. (2002). Fluoroquinolone-Induced Acute Interstitial Nephritis: Two Case Reports. The Canadian Journal of Hospital Pharmacy, 55.

Mahase, E. (2020). Covid-19: People with history of significant allergic reactions should not receive Pfizer vaccine, says regulator. British Medical Journal, 371.

Mahipathy, S. R. V., Durairaj, A. R., Sundaramurthy, N., Ramachandran, M., & Natarajan, P. G. (2019). Lyell’s syndrome: a rare case report. International Surgery Journal.

Martínez-Aranguren, R., Gamboa, P., García-Lirio, E., Alonso, A., & Sanz, M. (2012). In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Annals of Allergy, Asthma & Immunology, 108 4, 280–281.

Mathews, H. G., & Tancil, C. G. (1996). Extrapyramidal Reaction caused by Ondansetron. The Annals of Pharmacotherapy, 30, 196–196.

Monti, G., Viola, S., Tarasco, Lupica, M., Cosentino, & Castagno, E. (2011). A case of severe allergic reaction to cooked potato. Acta Paediatrica, 100.

Mumoli, N., Cei, M., Luschi, R., Carmignani, G., & Camaiti, A. (2011). Allergic reaction to Croscarmellose sodium used as excipient of a generic drug. QJM : Monthly Journal of the Association of Physicians, 104 8, 709–710.

Nakao, A., Nakao, A., Nakamura, Y., & Shibata, S. (2015). The circadian clock functions as a potent regulator of allergic reaction. Allergy. European Journal of Allergy and Clinical Immunology, 70, 467–473.

Neki, N., Kumar, J., Jain, A., Bajaj, R., Manav, M., Kumar, H., & Chavan, V. (2016). Allopurinol Induced Stevens – Johnson Syndrome: A Rare Case Report. Kerala Medical Journal, 9, 40–42.

Sampath, V., Rabinowitz, G., Shah, M. M., Jain, S., Diamant, Z., Jeseňák, M., Rabin, R., Vieths, S., Agache, I., Akdiş, M., Barber, D., Breiteneder, H., Chinthrajah, S., Chivato, T., Collins, W., Eiwegger, T., Fast, K., Fokkens, W., O’Hehir, R., … Nadeau, K. (2021). Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives. Allergy. European Journal of Allergy and Clinical Immunology, 76, 1640–1660.

Scavone, C., Mauro, C. D., Ruggiero, R., Bernardi, F., Trama, U., Aiezza, M., Rafaniello, C., & Capuano, A. (2019). Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. Drugs – Real World Outcomes, 7, 41–51.

Sharma, P., Gupta, N., Hasan, N., Krishnamurthy, B., & Singh, S. (2016). Hypersensitivity with Inhalational Budesonide: An Under Recognised Entity. Journal of Clinical and Diagnostic Research : JCDR, 10 10, FD01–FD02.

Shavit, R., Maoz-Segal, R., Iancovici-Kidon, M., Offengenden, I., Yahia, S. H., Maayan, D. M., Lifshitz-Tunitsky, Y., Niznik, S., Frizinsky, S., Deutch, M., Elbaz, E., Genaim, H., Rahav, G., Levy, I., Belkin, A., Regev-Yochay, G., Afek, A., & Agmon-Levin, N. (2021). Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Network Open, 4.

Shimabukuro, T., & Team, C. C.-R. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR. Morbidity and Mortality Weekly Report, 70, 46–51.

Shittu, M., Shah, P., Elkhalili, W., Suleiman, A., Shaaban, H., Shah, P. A., & Shamoon, F. (2015). A Rare Case of Recurrent Pacemaker Allergic Reaction. Heart Views, 16, 59–61.

Sivordova, L., Polyakova, Y., Papichev, E., Akhverdyan, Y., & Zavodovskii, B. V. (2021). Modern facilities of pharmacological correction of hyperuricemia in rheumatic diseases: management of difficult clinical cases. Meditsinskiy Sovet Medical Council.

Skypala, I., Bartra, J., Ebo, D., Faber, M., Fernández-Rivas, M., Gomez, F., Luengo, O., Till, S., Asero, R., Barber, D., Cecchi, L., Perales, A. D., Hoffmann‐Sommergruber, K., Pastorello, E., Swoboda, I., Konstantinopoulos, A., Ree, R., & Scala, E. (2021). The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins. Allergy. European Journal of Allergy and Clinical Immunology, 76.

Smith, C. (2023). Allergic Contact Dermatitis. Springer Berlin Heidelberg.

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M., Barber, D., Giacco, S. D. D., Jutel, M., Nadeau, K., Palomares, Ó., Rabin, R., Riggioni, C., Vieths, S., Agache, I., & Shamji, M. (2021). EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines. Allergy. European Journal of Allergy and Clinical Immunology, 76, 1629–1639.

Sprung, J., Weingarten, T., & Schwartz, L. (2015). Presence or absence of elevated acute total serum tryptase by itself is not a definitive marker for an allergic reaction. Anesthesiology, 122 3, 713–714.

Stamp, L., & Barclay, M. (2018). How to prevent allopurinol hypersensitivity reactions? Rheumatology, 57 suppl_1, i35–i41.

Tohyama, M., & Hashimoto, K. (2001). [Hypersensitivity syndrome and HHV-6]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 59 11, 2285–2292.

Tournikioti, K., Douzenis, A., Antoniadou, A., Papazahos, K., Moschos, C., Papageorgiou, C., & Rizos, E. (2016). Eosinophilia Associated With Olanzapine. Journal of Clinical Psychopharmacology, 36 2, 180–181.

Wang, H., Wang, H., & Liu, Z. P. (2011). Agents that induce pseudo-allergic reaction. Drug Discoveries & Therapeutics, 5 5, 211–219.

Warren, C., Snow, T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., Betts, B., Buzzanco, A., Gonzalez, J. C., Chinthrajah, R., Do, E., Chang, I., Dunham, D., Lee, G. M., O’Hara, R., Park, H. K., Shamji, M., Schilling, L., Sindher, S., … Nadeau, K. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Network Open, 4.

Winter, R., Bent, S. V. D., Esch, M., Wolkerstorfer, A., & Rustemeyer, T. (2019). Allergic Reaction to Red Cosmetic Lip Tattoo Treated With Hydroxychloroquine. Dermatitis.

Ильиных, Е. В., Владимиров, С. А., & Елисеев, М. С. (2017). Фебуксостат в терапии подагры: от теории к практике. Modern Rheumatology Journal, 11, 83–88.

« Older Entries